{"id":"NCT03352323","sponsor":"Padagis LLC","briefTitle":"An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea","officialTitle":"Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-18","primaryCompletion":"2017-12-06","completion":"2018-03-30","firstPosted":"2017-11-24","resultsPosted":"2021-01-05","lastUpdate":"2021-11-08"},"enrollment":50,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea","Erythema"],"interventions":[{"type":"DRUG","name":"Oxymetazoline","otherNames":[]}],"arms":[{"label":"oxymetazoline cream","type":"EXPERIMENTAL"}],"summary":"the study will measure the decrease in redness on the face of rosacea subjects","primaryOutcome":{"measure":"Responder","timeFrame":"Day 15","effectByArm":[{"arm":"Oxymetazoline Cream","deltaMin":16.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Headache"]}}